The partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India
Akums Drugs & Pharmaceuticals has partnered with Leiutis Pharmaceuticals and Biophore India Pharmaceuticals for the research and development of a range of products for multiple therapies. This association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner. This partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India.
Akums Drugs & Pharmaceuticals deals in the manufacturing and export of formulations in a wide spectrum of dosage forms and therapeutic segments. Akums has emerged as an integrated solution provider for companies seeking solutions around formulation manufacturing and advanced solutions for formulation development and testing. With a crème-de-la-crème of dedicated pharmaceutical personnel and standardized practices, Akums has been successful in attaining national and international accreditations and building trust based on efficacy, safety and quality. The organisation is certified with EU-GMP and other various international accreditations AKUMS’ innovative manoeuvres spread across all stages of the life cycles of a product and concept. When it comes to novel ideas and executions, there is no limit that the company marks as the limit. In its R&D centres, Akums goes the full house to create innovation, be it for a product, technology, process or concept. the company undertakes, arranges clinical trials and does all it takes to get the better formulations mushroom in the market.
Akums with reach to different markets, operates 15 fully-certified, state-of-the-art manufacturing facilities across the country. This is coupled with the company’s expertise in manufacturing and commercialising virtually all types of formulations, such as tablets, capsules, oral liquids, injections, creams, ointments, etc.; this combines with LEIUTIS Pharmaceuticals, which is a pharmaceutical product innovation company that creates innovative products that advance treatment in specific therapeutic areas. The company rides on proven expertise in nanotherapeutics, a formidable R&D ecosystem, and a track record of innovation which supports the next generation of speciality medicines. Its proprietary drug delivery technology is a breath of fresh air in the industry, especially for the advancement of treatment in pain management, CNS disorders, cancer, immunomodulators, CVS disorders, hormonal disorders and supportive care.; and with Biophore Pharmaceuticals, which is a is an established pharmaceutical company that develops and manufactures niche pharmaceutical products for the generic industry.
Biophore’s state-of-the-art, multipurpose active ingredient manufacturing facilities in India comply with cGMP standards and meet the requirements of the US and EU Drug regulatory authorities. Its technology development centre in Hyderabad is equipped with infrastructure that facilitates the entire process of drug research from conceptualisation to regulatory submissions. The company has filed over 100 drug master files and 150 patents for its unique portfolio. Biophore is one of the world’s leading API companies, ranking in the top 10 US DMF filers with the US FDA in the last five years.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPHI event and exhibition on the November 30, 2022 at Greater Noida in the presence of Prof (Dr) YK Gupta, President AIIMS Bhopal & President AIIMS Jammu & Former Dean & HoD Pharmacology, AIIMS Delhi.
“India has a significant contribution to the global pharma market and is rightly named the Pharmacy of the world. Global companies are looking towards India for differentiated research and innovative therapies. I am excited to know that Leiutis, Biophore and Akums have collaborated to introduce such differentiated and speciality products. The entire process, from basic Research API development and product manufacturing, is based in India. This is exactly what is exciting for India and expected from Indian entrepreneurs. The innovative products from this association will bring laurels to the Indian pharma industry.”
A significantly large number of patients suffer from these diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options. In association with LEIUTIS and BIOPHORE, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes,” said Sanjeev Jain, Founder, Promoter and Director, Akums.
As Dr Jagadeesh Babu Rangisetty, Founder and CEO, Biophore observes, it is imperative to form such partnerships to bring innovative products to the medical fraternity and patients. “It’s such an exciting prospect to partner with two other amazing organisations in the global pharma space. The aim is to combine our key competencies, capacities, and our passion for providing new therapies globally proven through clinical outcomes and to improve the lives of patients,” he said.
“Innovative therapies should address two objectives; ameliorate suffering and improve quality of life. Innovation is a collaborative journey and I am excited to be part of this journey. I am overwhelmed with the impact this association will make by creating value through clinically proven innovations for healthcare providers & patients. Through this association, I look forward to enabling our vision of fostering the well-being of patients through research and innovation. It gives me immense pride to mention that the products, technology, APIs, and manufacturing are developed & made in India,” said K Chandrasekhar, CEO, Leiutis Pharmaceuticals.
The tripartite association will see Akums manufacture & commercialise the products created by Leiutis Pharmaceuticals and API from Biophore.
These unique products will be launched and marketed in India and the rest of the world, in line with our government’s vision to ”Research in India, Make-in-India, Market globally” especially because of its potential to bring about useful therapies and bridge the gaps in the treatment of ailments and diseases across the world.
